Search bioRxiv⌕ Search

bioRxiv · 10.1101/2023.12.04.569940

The SCN8A p.(Gly1625Arg) variant associated with developmental and epileptic encephalopathy causes complex biophysical changes and reduced neuronal firing

Abstract

BackgroundMutations in the SCN8A gene, encoding the voltage-gated sodium channel NaV1.6, lead to various neurodevelopmental disorders. The SCN8A p.(Gly1625Arg) mutation (NaV1.6G1625R) was identified in a patient diagnosed with developmental epileptic encephalopathy (DEE), presenting with moderate epilepsy and severe developmental delay. MethodsWe performed biophysical and neurophysiological characterizations of NaV1.6G1625R in Neuro-2a cells and cultured hippocampal neurons, followed by computational modeling to determine the impact of its heterozygous expression on cortical neuron function. FindingsVoltage-clamp analyses of NaV1.6G1625R demonstrated a heterogeneous mixture of gain-and loss-of-function properties, including reduced current amplitudes, a marked increase in the time constant of fast voltage-dependent inactivation and a depolarizing shift in the voltage dependence of inactivation. Recordings in transfected cultured neurons showed that these intricate biophysical properties had a minor effect on neuronal excitability when firing relayed on both endogenous and transfected NaV channels. Conversely, there was a marked reduction in the number of action potentials when firing was driven by the transfected mutant NaV1.6 channels. Computational modeling of mature cortical neurons further revealed a mild reduction in neuronal firing when mimicking the patients heterozygous NaV1.6G1625R expression. Structural modeling of NaV1.6G1625R and a double-mutant cycle analysis suggested the possible formation of pathophysiologically-relevant cation-{pi} interaction between R1625 and F1588, affecting the voltage dependence of inactivation. InterpretationOur analyses demonstrate a complex combination of gain and loss-of-function changes resulting in an overall mild reduction in neuronal firing, related to a perturbed interaction network within the voltage sensor domain. FundingISF, DFG, BMBF, The Hartwell Foundation, ICRF, ISCA Research in contextO_ST_ABSEvidence before this studyC_ST_ABSMutations in the SCN8A gene, encoding the voltage-gated sodium channel NaV1.6, result in multiple neurodevelopmental syndromes ranging from benign epilepsy to developmental delay without epilepsy or developmental epileptic encephalopathy (DEE). Recent studies established that most DEE-causing SCN8A mutations result in a gain of function effect. However, several SCN8A mutations that diverge from this pattern were described. Added value of this studyWe performed a multi-tiered study of the SCN8A p.(Gly1625Arg) variant (NaV1.6G1625R), identified in a patient with atypical DEE presentation, featuring moderate epilepsy that is well controlled by the sodium channel blocker Oxcarbazepine, along with profound stagnated developmental delay. This variant is positioned within the S4 segment of domain IV, a critical region for NaV1.6 function, where pathogenic variants were shown to cause either a loss or gain of channel function, but often with mixed biophysical alterations. Our biophysical characterization of NaV1.6G1625R in Neuro-2a cells demonstrated complex gain-and loss-of-function properties, cumulating to reduced firing in cultured hippocampal neurons and computational modeling of mature cortical neurons, demonstrating an overall loss-of-function effect. Implications of all the available evidenceOur results indicate the necessity for combined biophysical and neuronal characterization of individual SCN8A variants, especially those presenting with complex biophysical changes or atypical clinical presentation. Moreover, while sodium channel blockers are the recommended treatment for SCN8A variants associated with gain-of-function, additional considerations may be needed for DEE-causing variants that are associated with mild loss-of-function.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Quinn, S., Zhang, N., Fenton, T. A., Brusel, M., Muruganandam, P., Peleg, Y., Giladi, M., Haitin, Y., Lerche, H., Bassan, H., Liu, Y., Ben-Shalom, R., Rubinstein, M.. 2023-12-05. The SCN8A p.(Gly1625Arg) variant associated with developmental and epileptic encephalopathy causes complex biophysical changes and reduced neuronal firing. https://doi.org/10.1101/2023.12.04.569940

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

Cholinergic impairment in the dorsal motor nucleus of the vagus during experimental Alzheimer's disease

Cholinergic neurons in the dorsal motor nucleus of the vagus (DMN) in the brainstem are a key source of efferent vagus nerve fibers that regulate vital functions, including heart rate and inflammation. Whether the integrity of DMN cholinergic neurons is affected during Alzheimer's disease (AD) remains unknown. Here, in female and male mice with experimental AD (5xFAD), which exhibit age-dependent memory impairment, basal forebrain cholinergic neurodegeneration, and microglial alterations, we observe a reduction in cholinergic neuron density in the DMN at 6 and 10 months of age. Furthermore, while an important physiological function of DMN cholinergic signaling, such as suppression of heart rate, is preserved in control mice upon electrical DMN stimulation, the extent of suppression diminishes with age in both female and male 5xFAD mice. In addition, while electrical DMN stimulation lowers pro-inflammatory cytokine levels in control mice subjected to endotoxemia, this anti-inflammatory effect is diminished with age in 5xFAD mice, with females showing earlier dysfunction at 6 months. These results reveal previously unrecognized age-dependent cholinergic deficits in the DMN and disrupted brain - to - periphery vagus nerve circuits in experimental AD. These findings advance our understanding of AD mechanisms and are of interest for the development of conceptually novel therapies.

physiology↗

Ketogenic diet is protective during endotoxin-induced lung injury through the elevation of BHB

Acute respiratory distress syndrome (ARDS) is marked by severe pulmonary edema and concomitant hypoxia, affecting hundreds of thousands of people a year, especially those in critical care conditions or suffering from septic shock. Previous studies have implicated that the ketogenic diet, a high-fat and low-carbohydrate diet, modulates inflammatory responses. However, the impact of the ketogenic diet on septic ARDS outcomes is unknown. Here, we demonstrated that mice on a ketogenic diet showed strikingly reduced lung injury and inflammation compared to those on a control diet during a murine model of endotoxin-induced lung injury, induced by intratracheal lipopolysaccharide (LPS) injection. Immune mass cytometry studies on lung tissue indicated that the ketogenic diet reduces immune cell infiltration. Treating mice with beta-hydroxybutyrate (BHB), the primary metabolite of ketogenesis, after the onset of ARDS reduced pulmonary edema and lung inflammation, as well as NF-kB activity, suggesting strong therapeutic potential. By multiplex analysis in bronchial alveolar lavage fluid, we observed that the ketogenic diet or BHB administration attenuates the chemotaxis and activation of immune cells. Altogether, our findings reveal that the ketogenic diet provides lung protection during endotoxin-induced lung injury through BHB.

physiology↗

Efficacy of postmenopausal estrogen replacement in SIV-infected female macaques on antiretroviral therapy.

The success of modern antiretroviral therapy (ART) has increased the life expectancy of people living with HIV to levels approaching that of uninfected individuals. For women living with HIV (WLWH), this means that more will survive to undergo menopause and experience the consequences of decreased ovarian hormone levels, particularly estrogen (E2). The recent change in federal guidance for use of postmenopausal hormone therapy is increasing demand for both E2-alone and E2+progestogen formulations to control adverse symptoms of menopause. The consequences and efficacy of hormone therapy in WLWH are thus an important issue for WLWH and their healthcare providers. The role of E2 replacement in postmenopausal WLWH is a significant issue because of its potential effects on control the viral reservoir and its demonstrated beneficial metabolic effects in uninfected postmenopausal women. To address these questions, we employed a novel nonhuman primate model of postmenopausal WLWH undergoing E2 replacement. Reproductively competent female rhesus macaques were infected with simian immunodeficiency virus (SIV) and then subjected to a daily ART regimen. After complete suppression of plasma viremia, all animals were ovariectomized (OVX) and then implanted with Silastic capsules containing either cholesterol vehicle or sufficient E2 to restore pre-OVX plasma levels. Plasma and cell-associated viral dynamics, immune responses, body composition, systemic and tissue-specific metabolic parameters, cytokine profiles, and parameters of bone health were followed longitudinally from baseline through 34 weeks of E2 deficiency or replacement. We found that E2 status did not significantly affect plasma or tissue viral dynamics or overall metabolic homeostasis. However, E2 replacement exerted beneficial effects on several aspects of bone health in spite of a chronic inflammatory state that persisted following effective ART suppression of the SIV reservoir. Our findings suggest that hormone therapy, specifically E2 replacement, offers benefit to WLWH, particularly with respect to bone loss.

physiology↗